title: Cardiovascular effects of a trandolapril/verapamil combination in patients with mild to moderate essential hypertension.
abstract: The cardiovascular effects of a combination of trandolapril and verapamil were evaluated in 14 patients with mild to moderate essential hypertension. This combination therapy decreased arterial pressure mainly through a decrease in total peripheral resistance without causing an increase in heart rate or cardiac output: left ventricular mass was significantly reduced, cardiac systolic function improved, and plasma volume and renal blood flow remained unchanged.
authors.affiliation: Department of Internal Medicine, Ochsner Clinic and Alton Ochsner Medical Foundation, New Orleans, Louisiana 70121, USA.
authors.forename: F C
authors.initials: FC
authors.lastname: Aepfelbacher
authors.forename: F H
authors.initials: FH
authors.lastname: Messerli
authors.forename: E
authors.initials: E
authors.lastname: Nunez
authors.forename: L
authors.initials: L
authors.lastname: Michalewicz
mesh_terms: D000368:Aged; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D002121:Calcium Channel Blockers / Q000627:therapeutic use*; D002319:Cardiovascular System / Q000187:drug effects* / Q000503:physiopathology; D003692:Delayed-Action Preparations; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000503:physiopathology; D007211:Indoles / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D013997:Time Factors; D014700:Verapamil / Q000627:therapeutic use*
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D002121:Calcium Channel Blockers; D003692:Delayed-Action Preparations; D007211:Indoles; C052035:trandolapril; D014700:Verapamil